Skip to content
Homepage
Author:
DIAGONAL THERAPEUTICS, INC
Posted Date:
July 16, 2026
Diagonal Therapeutics Announces First Patient Dosed in Phase 1/2 DIAMOND Clinical Trial of DIAG723 for Hereditary Hemorrhagic Telangiectasia (HHT)
DIAGONAL THERAPEUTICS, INC
July 16, 2026
Diagonal Therapeutics Expands Executive Leadership Team, Appoints Industry Veteran Jonathan Piazza as Chief Financial Officer
DIAGONAL THERAPEUTICS, INC
May 5, 2026
